age-related macular degeneration

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

Lampalizumab (RG 7417) is a humanized monoclonal antibody targeting Complement Factor D in the complement pathway, used in age-related macular degeneration (AMD) and cardiovascular disease research.

Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.

Tarcocimab (OG1953), a humanized IgG1-type anti-VEGFA monoclonal antibody, is utilized in research targeting conditions such as retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

Galegenimab (RG 6147) is an antigen-binding fragment (Fab) targeting HtrA1, capable of blocking proteolytic cleavage of biglycan (an HtrA1 substrate), suitable for age-related macular degeneration (AMD) research.

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).

BAT5906 is a human monoclonal antibody (mAb) that targets VEGFA. It can be utilized in research on wet age-related macular degeneration and diabetic macular edema.

UBX2050 is a human monoclonal antibody (mAb) that targets TIE2. It is applicable in research concerning age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

ASKG-712 (AM712) is a recombinant humanized monoclonal antibody (mAb) combined with an Ang-2 antagonist peptide fusion protein. It is utilized in research focused on wet age-related macular degeneration and diabetic macular edema.

MW02 is a human monoclonal antibody (mAb) targeting VEGFA. It is applicable in the study of wet age-related macular degeneration.

PF-04382923 is a humanized IgG2Δa monoclonal antibody. It binds with high affinity to the free C-terminal region of amyloid β (Aβ) peptides Aβ1-40 and Aβ1-42. PF-04382923 is utilized in research concerning geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD).